Abiraterone acetate 250 MG Oral Tablet [Zytiga] — RxCUI 1100079
RxNorm drug concept · Semantic branded drug
RxCUI 1100079
Semantic branded drug · SBD
● Current RxNorm concept 2 FDA products
3 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1100079
Official nameAbiraterone acetate 250 MG Oral Tablet [Zytiga]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asZytiga 250 MG Oral Tablet
FDA products mapped2
Package NDCs mapped3
Reported Medicaid activity (SDUD)402 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Abiraterone: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Abiraterone blocks an enzyme that prostate cancer cells use to make the male hormones they need to grow — not just in the testes, but also in the adrenal glands and in the tumor it...
- What exactly does abiraterone do, and why do I need to take it with prednisone?
- Yes, this is really important and it depends on which product you have. Most abiraterone tablets — including Zytiga, Abirtega, and the generics — must be taken on a completely empt...
- Does it matter when I eat? My neighbor takes a different abiraterone and he eats with it.
🕸️ Concept Web — How Abiraterone acetate 250 MG Oral Tablet [Zytiga] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Abiraterone acetate 250 MG Oral Tablet [Zytiga]
RxCUI 1100079 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Abiraterone
1100072IN -
Abiraterone acetate
1100071PIN
-
Abiraterone
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Zytiga
1100076BN
-
Zytiga
-
Dose forms 13
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Abiraterone Oral Tablet
1100074SCDF -
Abiraterone acetate Oral Tablet
2646523SCDFP -
Abiraterone Oral Product
1163656SCDG -
Abiraterone Pill
1163657SCDG -
Abiraterone acetate Oral Product
2661457SCDGP -
Abiraterone acetate Pill
2662678SCDGP -
Abiraterone Oral Tablet [Zytiga]
1100078SBDF -
Abiraterone acetate Oral Tablet [Zytiga]
2655185SBDFP - +5 more in this family
-
Abiraterone Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Abiraterone acetate 250 MG Oral Tablet
1100075SCD -
Abiraterone acetate 250 MG
1100073SCDC -
Abiraterone acetate 250 MG [Zytiga]
1100077SBDC
-
Abiraterone acetate 250 MG Oral Tablet
Showing up to 8 concepts per family — 14 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Abiraterone acetate 250 MG Oral Tablet
SCD · 1100075 -
Abiraterone acetate 250 MG
SCDC · 1100073 -
Abiraterone Oral Tablet
SCDF · 1100074 -
Abiraterone acetate Oral Tablet
SCDFP · 2646523 -
Abiraterone Oral Product
SCDG · 1163656 -
Abiraterone Pill
SCDG · 1163657 -
Abiraterone acetate Oral Product
SCDGP · 2661457 -
Abiraterone acetate Pill
SCDGP · 2662678
Brand-Name Concepts
-
Abiraterone acetate 250 MG [Zytiga]
SBDC · 1100077 -
Abiraterone Oral Tablet [Zytiga]
SBDF · 1100078 -
Abiraterone acetate Oral Tablet [Zytiga]
SBDFP · 2655185 -
Zytiga Oral Product
SBDG · 1186683 -
Zytiga Pill
SBDG · 1186684 -
Zytiga
BN · 1100076
📦 FDA Products & Package NDCs
2 products · 3 package NDCs
3 package NDCs map to RxCUI 1100079 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 57894-0150-12 | 120 TABLET in 1 BOTTLE (57894-150-12) | Zytiga | Janssen Biotech, Inc. | 2011-04-28 |
| 57894-0195-06 | 60 TABLET, FILM COATED in 1 BOTTLE (57894-195-06) | Zytiga | Janssen Biotech, Inc. | 2017-04-17 |
| 57894-0195-15 | 60 TABLET, FILM COATED in 1 BOTTLE (57894-195-15) | Zytiga | Janssen Biotech, Inc. | 2017-04-17 |
Observed labelers:
Janssen Biotech, Inc. (3)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.